Citadel Advisors’s Beta Bionics BBNX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.96M Buy
+103,450
New +$1.86M ﹤0.01% 6746
2026
Q2
– Sell
-52,142
Closed -$620K – 15216
2026
Q1
$522K Sell
52,142
-268,738
-84% -$3.97M ﹤0.01% 9195
2025
Q4
$9.8M Buy
+320,880
New +$8.57M ﹤0.01% 3283
2025
Q3
– Sell
-539,963
Closed -$7.86M – 14518
2025
Q2
$7.86M Sell
539,963
-406,387
-43% -$5.75M ﹤0.01% 3378
2025
Q1
$11.6M Buy
+946,350
New +$17.6M ﹤0.01% 2663

Other funds holding BBNX

Citadel Advisors's BBNX Position: Q3 2026 in Review

Citadel Advisors opened a new position in Beta Bionics (BBNX) in Q3 2026: 103,450 shares worth $1.96M. The stake represents ﹤0.01% of the portfolio and ranks #6746 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in BBNX as recently as Q1 2026.

Citadel Advisors first reported a position in BBNX in Q1 2025 and has held it in 5 quarters since. The position peaked at $11.6M in Q1 2025. 153 funds tracked by Wall St. Rank hold BBNX as of Q3 2026.

  • Citadel Advisors held 103,450 shares of Beta Bionics worth $1.96M as of Q3 2026.
  • Beta Bionics was a new Citadel Advisors position in Q3 2026.
  • Beta Bionics made up ﹤0.01% of Citadel Advisors's portfolio in Q3 2026, its #6746 holding.
  • Citadel Advisors first reported a position in Beta Bionics in Q1 2025 and has held it in 5 quarters since.
  • Citadel Advisors's Beta Bionics position peaked at $11.6M in Q1 2025.
  • 153 funds tracked by Wall St. Rank held Beta Bionics as of Q3 2026.

Based on Citadel Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.